Can slow personalized titration using C-Reactive Protein monitoring decrease the high rates and mortality of clozapine-associated myocarditis seen in some countries? A call for research.

Other countries have very limited published data on clozapine-associated myocarditis. Based on a recent Australian case series and these non-Australian studies, the author proposes that Australia (and other countries) should use slow personalized titration for clozapine based on ancestry and c-reactive protein monitoring.